Antiangiogenic Cancer Therapy 1st Edition Darren W Davis Roy S Herbst by Darren W. Davis, Roy S. Herbst, James L. Abbruzzese 9780849327995, 0849327997 instant download after payment.

The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important questions about the complexities inherent in the clinical application of angiogenesis inhibitors.

Compiles the results of four decades of progress

Integrating fundamental concepts with therapeutic strategies, Anti-Angiogenic Cancer Therapy promotes the idea that an understanding of the molecular and cellular regulation of angiogenesis leads to optimal therapeutic strategies and positive clinical results. It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject.

This volume celebrates progress made in four decades, and more importantly, it provides a clear indication of the complex biology that needs further investigation to realize the possibilities envisioned for this beneficial therapeutic modality.